Directive on the legal protection of biotechnological inventions

Last updated

Directive 98/44/EC
European Union directive
Flag of Europe.svg
TitleDirective on the legal protection of biotechnological inventions
Made by European Parliament & Council
Made underArt. 100a
Journal reference L213, 30 July 1998, pp. 13–21
History
Date made1998-07-06
Came into force1998-07-30
Implementation date2000-07-30
Preparative texts
Commission proposalC296, 1996-10-08, p. 4.
C311, 1997-10-11, p. 12.
EESC opinionC295, 1996-10-07, p. 11
EP opinionC286, 1997-09-22, p. 87.
C167, 1998-06-01
ReportsCOM(2002) 2
COM(2002) 545
COM(2005) 312
Other legislation
Replaces—
Amends—
Amended by—
Replaced by—
Current legislation

Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions is a European Union directive in the field of patent law, made under the internal market provisions of the Treaty of Rome. It was intended to harmonise the laws of Member States regarding the patentability of biotechnological inventions, including plant varieties (as legally defined) and human genes.

Contents

Content

The Directive is divided into the following five chapters:

Timeline

The original proposal was adopted by the European Commission in 1988. The procedure for its adoption was slowed down by primarily ethical issues regarding the patentability of living matter. The European Parliament eventually rejected the joint text from the final Conciliation meeting at 3rd reading on 1 March 1995 so the first directive process did not yield a directive. [1]

On 13 December 1995, the Commission adopted a new proposal was nearly identical to the rejected version, was changed again, but the Parliament put aside its ethical concerns on patenting of human genes in on 12 July 1998 in its second reading and adopted the Common Position of the Council, so in the second legislative process, the directive was adopted. [2] [3] The drafts person of the Parliament for this second procedure was Willi Rothley and the vote with the most yes votes was Amendment 9 from the Greens which got 221 against 294 votes out of 532 members voting with 17 abstentions but 314 yes votes would have been required to reach the required an absolute majority to adopt it.

On 6 July 1998, a final version was adopted. Its code is 98/44/EC.

The Kingdom of the Netherlands brought Case C-377/98 [4] before the European Court of Justice against the adoption of the directive with six different pleas but the Court granted none of them.

Nevertheless, the ECJ decision does not preclude a further test of the validity of the directive on the ground that it is inconsistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). [5] Art. 27.1 TRIPS provides that patents are only to be granted with respect to 'inventions'. The directive, however, provides that "biological material which is isolated from its natural environment ... may be the subject of an invention even if it previously occurred in nature." It is clearly arguable that merely isolating a human gene or protein from its natural environment is not an activity that can come within the meaning of the word 'invention'. The Danish Council of Bioethics in its Patenting Human Genes and Stem Cells Report [6] noted that "In the members' view, it cannot be said with any reasonableness that a sequence or partial sequence of a gene ceases to be part of the human body merely because an identical copy of the sequence is isolated from or produced outside of the human body." TRIPS applies to the European Community as it is a member of the World Trade Organization (WTO) in its own right and accordingly must ensure "the conformity of its laws, regulations and administrative procedures with obligations as provided" by the WTO. [7]

On 14 January 2002, the Commission submitted an assessment of the implications for basic genetic engineering research of failure to publish, or late publication of, papers on subjects which could be patentable as required under Article 16(b) of this directive. [8]

Campaigning and lobbying

According to SmithKline Beecham lobbyist Simon Gentry, the company allocated 30 million ECU for a pro-Directive campaign. [9] Part of this campaign was direct support of patient charities and organisations. On the day of the July 1997 vote, a number of people in wheelchairs from these groups demonstrated outside the main hall in Strasbourg, chanting the pharmaceutical industry's slogan, "No Patents, No Cure" in an emotional appeal to Parliamentarians to vote for the Directive. [10]

Implementation

As of 15 January 2007, all of the 27 EU member states had implemented the Directive. [11]

See also

Related Research Articles

The World Intellectual Property Organization Copyright Treaty is an international treaty on copyright law adopted by the member states of the World Intellectual Property Organization (WIPO) in 1996. It provides additional protections for copyright to respond to advances in information technology since the formation of previous copyright treaties before it. The WCT and WIPO Performances and Phonograms Treaty, are together termed WIPO "internet treaties".

Copyright Duration Directive

Council Directive 93/98/EEC of 29 October 1993 harmonising the term of protection of copyright and certain related rights is a European Union directive in the field of EU copyright law, made under the internal market provisions of the Treaty of Rome. It was replaced by the 2006 Copyright Term Directive (2006/116/EC).

European Union law

European Union law is a system of rules operating within the member states of the European Union. Since the founding of the Coal and Steel Community after World War II, the EU has developed the aim to "promote peace, its values and the well-being of its peoples". The EU has political institutions, social and economic policies, which transcend nation states for the purpose of cooperation and human development. According to its Court of Justice the EU represents "a new legal order of international law".

The Proposal for a Directive of the European Parliament and of the Council on the patentability of computer-implemented inventions, procedure number 2002/0047 (COD) was a proposal for a European Union (EU) directive aimed to harmonise national patent laws and practices concerning the granting of patents for computer-implemented inventions, provided they meet certain criteria.

EUR-Lex EUR-Lex is your online gateway to EU Law

Eur-Lex is an official website of European Union law and other public documents of the European Union (EU), published in 24 official languages of the EU. The Official Journal (OJ) of the European Union is also published on Eur-Lex. Users can access Eur-Lex free of charge and also register for a free account, which offers extra features.

Regulation (European Union)

A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law. Regulations can be adopted by means of a variety of legislative procedures depending on their subject matter.

The WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), particularly Article 27, is occasionally referenced in the political debate on the international legal framework for the patentability of software, and on whether software and computer-implemented inventions should be considered as a field of technology.

Proposed directive on criminal measures aimed at ensuring the enforcement of intellectual property rights

The European Union (EU) directive on criminal measures aimed at ensuring the enforcement of intellectual property rights (2005/0127/COD) was a proposal from the European Commission for a directive aimed "to supplement Directive 2004/48/EC of 29 April 2004 on the enforcement of intellectual property rights ". The directive was proposed on July 12, 2005 by the Commission of the European Communities.

European Union legislative procedure Procedures for the adoption of legislation in the European Union

The European Union adopts legislation through a variety of legislative procedures. The procedure used for a given legislative proposal depends on the policy area in question. Most legislation needs to be proposed by the European Commission and approved by the Council of the European Union and European Parliament to become law.

<i>European Pharmacopoeia</i>

The European Pharmacopoeia is a major regional pharmacopoeia which provides common quality standards throughout the pharmaceutical industry in Europe to control the quality of medicines, and the substances used to manufacture them. It is a published collection of monographs which describe both the individual and general quality standards for ingredients, dosage forms, and methods of analysis for medicines. These standards apply to medicines for both human and veterinary use.

European Union patent law is a subset of European patent law. It also serves as the superset of the patent laws of the individual member states of the European Union (EU). The most recent (proposed) addition to the range of measures currently in place is the Directive on criminal measures aimed at ensuring the enforcement of intellectual property rights. The most recent directive relating specifically to patents is Directive on the patentability of biotechnological inventions. Patents are probably the least harmonised area of intellectual property laws of the European Union insofar as harmonisation through EU Directives and Regulations is concerned. However, patentability criteria have been substantially harmonized by the European Patent Convention.

European Directive on Traditional Herbal Medicinal Products

The European Directive on Traditional Herbal Medicinal Products (THMPD), formally the Directive 2004/24/EC amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use, was established by the European Parliament and Council on 31 March 2004 to provide a simplified regulatory approval process for traditional herbal medicines in the European Union (EU). Previously, there was no formal EU wide authorisation procedure, so each EU member state regulated these types of products at the national level.

European Commissioner for Internal Market

The Commissioner for Internal Market is a member of the European Commission. The post is currently held by Commissioner Thierry Breton.

TRIPS Agreement International treaty on intellectual property protections

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international legal agreement between all the member nations of the World Trade Organization (WTO). It establishes minimum standards for the regulation by national governments of different forms of intellectual property (IP) as applied to nationals of other WTO member nations. TRIPS was negotiated at the end of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT) between 1989 and 1990 and is administered by the WTO.

Directive 2011/77/EU on the term of protection of copyright and certain related rights amended Directive 2006/116/EC and extended copyright terms of recordings from 50 to 70 years. It was passed by the Council of the European Union on 12 September 2011 after the European Parliament passed it on 23 April 2009 establishing a term of 70 years, lower than the 95 years the European Union Commission had proposed on 16 July 2008.

The European Union's Third Energy Package is a legislative package for an internal gas and electricity market in the European Union. Its purpose is to further open up the gas and electricity markets in the European Union. The package was proposed by the European Commission in September 2007, and adopted by the European Parliament and the Council of the European Union in July 2009. It entered into force on 3 September 2009.

Directive on intra-EU-transfers of defence-related products

Directive on intra-EU-transfers of defence-related products is a European Union Directive with relevance for the European Economic Area. "Transfer" in this context means "any transmission or movement of a defence-related product from a supplier to a recipient in another Member State".

Monsanto Technology LLC v Cefetra BV and Others (2010) was a preliminary ruling by the European Court of Justice (ECJ) regarding the legal protection of biotechnological inventions. The case dealt with the interpretation of Article 9 of Directive 98/44/EC on the legal protection of biotechnological inventions, and it was the first ECJ interpretation of the 1998 directive.

A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.

References

  1. ↑ "EURLex – 100993 – EN – EUR-Lex". European Commission. Retrieved 24 February 2015.
  2. ↑ "Part 1 : Proceedings of the sitting". European Parliament. Retrieved 24 February 2015.
  3. ↑ "EURLex – 11643 – EN – EUR-Lex". European Commission. Retrieved 24 February 2015.
  4. ↑ Archived 19 August 2007 at the Wayback Machine
  5. ↑ "intellectual property (TRIPS) – agreement text – contents". WTO. Retrieved 18 August 2013.
  6. ↑ Archived 10 October 2006 at the Wayback Machine
  7. ↑ "legal texts – Marrakesh agreement". WTO. Retrieved 18 August 2013.
  8. ↑ "EURLex – 170903 – EN – EUR-Lex". European Commission. 14 January 2002. Retrieved 24 February 2015.
  9. ↑ Industry and the EU Life Patent Directive Archived 29 June 2006 at the Wayback Machine , Corporate Europe Observer, Issue 1, May 1998, citing ECOBP, "The Big Mirage: The Misuse of the Patient with Hereditary Diseases Before the EP's Vote in 1997" an ECOBP Background Paper, March 1998, page 4
  10. ↑ Simpson, Alan (1 September 1997). "No Patents on Life". The Corner House. Retrieved 24 February 2015.
  11. ↑ "State of Play of the Implementation of Directive 98/44/EC" (PDF). European Commission. Retrieved 24 February 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.